HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Tian, J. Articles by Kaufman, D. L. Search for Related Content PubMed PubMed Citation Articles by Tian, J. Articles by Kaufman, D. L.

Attenuation of Inducible Th2 Immunity with Autoimmune Disease Progression¹

Department of Molecular and Medical Pharmacology, University of California, Los Angeles, CA 90095

Autoantigen-based immunotherapeutics have been shown to activate regulatory responses capable of inhibiting T cell-mediated autoimmune disease in animal models. However, their efficacy generally declines, as treatment occurs later in the disease process, and their mechanism of action is a matter of intense debate. Here, we report that the early administration of ß cell autoantigens (ßCAAs) to nonobese diabetic (NOD) mice broadly diverts the natural development of potentially pathogenic Th1-biased autoimmune responses toward the Th2 phenotype through Th2 spreading. With disease progression, there was a steady decline in the ability of ßCAA treatment to promote Th2-type cellular and humoral autoimmunity. Late in the disease process, some ßCAAs were still able to induce Th2 responses and Th2 spreading (although to a much lesser extent), while other autoantigens were not. This attenuation of inducible Th2 immunity with disease progression is likely to reflect a reduction in the availability of uncommitted autoantigen-reactive precursor T cells. These findings suggest that there are inherent differences in the frequency of ßCAA-reactive T cells and that, in advanced stages of autoimmune disease, regulatory responses may be best elicited with target tissue Ags against which large uncommitted T cell pools are still available. Since individuals presenting the first signs of autoimmune disease are likely to already have an advanced disease process, these findings may be useful for the rational design of Ag-based immunotherapeutics.

This article has been cited by other articles:

				J. Tian, H. Dang, H. von Boehmer, E. Jaeckel, and D. L. Kaufman Transgenically Induced GAD Tolerance Curtails the Development of Early {beta}-Cell Autoreactivities but Causes the Subsequent Development of Supernormal Autoreactivities to Other {beta}-Cell Antigens Diabetes, December 1, 2009; 58(12): 2843 - 2850. [Abstract] [Full Text] [PDF]

				J. Tian and D. L. Kaufman Antigen-Based Therapy for the Treatment of Type 1 Diabetes Diabetes, September 1, 2009; 58(9): 1939 - 1946. [Full Text] [PDF]

				A. P. Olcott, J. Tian, V. Walker, H. Dang, B. Middleton, L. Adorini, L. Washburn, and D. L. Kaufman Antigen-Based Therapies Using Ignored Determinants of {beta} Cell Antigens Can More Effectively Inhibit Late-Stage Autoimmune Disease in Diabetes-Prone Mice J. Immunol., August 1, 2005; 175(3): 1991 - 1999. [Abstract] [Full Text] [PDF]

				C. Seifarth, S. Pop, B. Liu, C. P. Wong, and R. Tisch More Stringent Conditions of Plasmid DNA Vaccination Are Required to Protect Grafted Versus Endogenous Islets in Nonobese Diabetic Mice J. Immunol., July 1, 2003; 171(1): 469 - 476. [Abstract] [Full Text] [PDF]

				F. J. Quintana, P. Carmi, and I. R. Cohen DNA Vaccination with Heat Shock Protein 60 Inhibits Cyclophosphamide-Accelerated Diabetes J. Immunol., November 15, 2002; 169(10): 6030 - 6035. [Abstract] [Full Text] [PDF]

				D. J. Weaver Jr., B. Liu, and R. Tisch Plasmid DNAs Encoding Insulin and Glutamic Acid Decarboxylase 65 Have Distinct Effects on the Progression of Autoimmune Diabetes in Nonobese Diabetic Mice J. Immunol., July 1, 2001; 167(1): 586 - 592. [Abstract] [Full Text] [PDF]

				W. S. Gallichan, B. Balasa, J. D. Davies, and N. Sarvetnick Pancreatic IL-4 Expression Results in Islet-Reactive Th2 Cells That Inhibit Diabetogenic Lymphocytes in the Nonobese Diabetic Mouse J. Immunol., August 1, 1999; 163(3): 1696 - 1703. [Abstract] [Full Text] [PDF]

				M. Paas-Rozner, M. Sela, and E. Mozes The nature of the active suppression of responses associated with experimental autoimmune myasthenia gravis by a dual altered peptide ligand administered by different routes PNAS, October 23, 2001; 98(22): 12642 - 12647. [Abstract] [Full Text] [PDF]